Examining how personality affects medication adherence in chronic myeloid leukemia patients
Official title: Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Run by University of California, Irvine · NCT06229860 · Data updated 2026-11-12
This study is trying to see how different personality traits affect whether people with chronic myeloid leukemia stick to their medication plan.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | University of California, Irvine Academic / other |
| Drugs / interventions | imatinib, dasatinib, bosutinib, nilotinib |
| Locations | 1 site (Orange, California) |
| Status | Recruiting |
| Started | January 25, 2024 |
| Main results expected | March 19, 2025 |
| Study ends | December 2026 |
| Registry record updated | March 10, 2026 |
| Trial ID | NCT06229860 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have been diagnosed with chronic myeloid leukemia and are currently receiving treatment with specific tyrosine kinase inhibitors.
✕Probably not a fit
Patients who are unable to read and speak English or have impaired decisional capacity to consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational pilot study aims to investigate the relationship between personality traits and adherence to tyrosine kinase inhibitor therapy in patients diagnosed with chronic myeloid leukemia (CML). A total of 75 individuals in the chronic phase of CML will be recruited and participate in focused interviews. During these interviews, researchers will assess TKI adherence, personality types, quality of life, and symptom burden using validated questionnaires. Additionally, treatment response data and physician perceptions of adherence will be collected from electronic health records.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how personality influences medication adherence, potentially leading to tailored interventions that improve treatment outcomes for CML patients.
How similar studies have gone: While the specific focus on personality and TKI adherence is novel, previous studies have explored factors influencing medication adherence in cancer patients, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP) * Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib * A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or * A member of a patient support group organized by the CML Buster Foundation * Do not meet any of the criteria listed under "Exclusion Requirements" Exclusion Criteria: * Unable to read and speak English * Impaired decisional capacity to consent
Where it's running
-
Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, United States Recruiting
Study contacts
- Principal investigator: Mahtab Jafari, Pharm.D — Chao Family Comprehensive Cancer Center
- Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
- Email: ucstudy@uci.edu
- Phone: 1-877-827-8839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dasatinib plus ropeginterferon for newly diagnosed chronic myeloid leukemia in chronic phase
This study tests whether the drug combination dasatinib and ropeginterferon can help control chronic myeloid leukemia in adults with newly diagnosed disease.
-
Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant
This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.
-
Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor
This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.
-
CBX-250 for relapsed or refractory myeloid leukemias.
This will try CBX-250, a new injectable medicine, in people aged 12 and older with relapsed or refractory AML, high-risk MDS, CMML, or CML to see if it can control disease with tolerable side effects.
-
Olverembatinib monotherapy for adults with newly diagnosed chronic-phase CML
We are testing whether olverembatinib can control disease and produce deep molecular responses in adults newly diagnosed with chronic-phase CML.
-
Using Sorafenib to Prevent Relapse After Stem Cell Transplantation
This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.